Erin D. Michos, MD, discusses the clinical implications of results presented at ACC 2022 in the field of lipid management. Dr Michos sees a great opportunity with the results of the APOLLO trial, which addresses an unmet need for therapeutic options in reducing lipoprotein (a) in her patients.
Dr Michos also reviews the subanalysis of the CANTOS study which evaluated the interleukin-1 (IL-1) beta inhibitor canakinumab in patients with chronic kidney disease (CKD). In looking at what is to come, Dr Michos also notes the ongoing phase 3 ZEUS trial which is evaluating IL-6 inhibitors in patients with CKD at high risk for atherosclerotic cardiovascular disease.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ACC 2022: Unmet Needs and Emerging Therapies in Lipid Management - Medscape - May 04, 2022.
Comments